Clinical trial
Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With…
NCT00077376 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00077376 |
|---|---|
| Title | Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer |
| Official title | A Phase II Trial of Trastuzumab Plus Weekly Ixabepilone(BMS-247550) and Carboplatin in Patients With HER2/Neu-Positive Metastatic Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | trastuzumab, ixabepilone, carboplatin, laboratory biomarker analysis |
| Enrollment | 61 |
| Start date | Mar 1, 2005 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2011 |
| First posted | Feb 12, 2004 |
| Last update posted | May 21, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: